Takeda Pharmaceutical Co. Ltd. and Resolve Therpeutics have entered into a partnership to develop compounds for the treatment of lupus and other autoimmune diseases. The lead compound, RSLV-132, a novel nuclease Fc fusion protein, will begin clinical development later this year. Resolve has additional candidates in preclinical development that target autoantibody-containing immune complexes, which are thought to be the most frequent trigger of lupus.   Resolve will conduct all development work t...